Clinical Trials · NCT01115920
Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Stealth BioTherapeutics Inc.
- Enrollment
- 40
- Start date
- May 2010
- Locations
- 1 site, United States
- Primary endpoint
- Treatment emergent adverse events in treatment group versus placebo group